Lynx1 Capital Management LP Allogene Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $270 Million
- Q1 2025
A detailed history of Lynx1 Capital Management LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 11,057,009 shares of ALLO stock, worth $13.7 Million. This represents 5.97% of its overall portfolio holdings.
Number of Shares
11,057,009
Previous 10,874,723
1.68%
Holding current value
$13.7 Million
Previous $23.2 Million
30.31%
% of portfolio
5.97%
Previous 9.0%
Shares
4 transactions
Others Institutions Holding ALLO
# of Institutions
177Shares Held
165MCall Options Held
202KPut Options Held
76.6K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$23.2 Million0.84% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$20.4 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA12.3MShares$15.2 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.4MShares$13 Million1.06% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il10.2MShares$12.7 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $178M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...